Nippon Shinyaku Co. Ltd. has taken up its option on U.S. rights to AB2 Bio Ltd.’s interleukin-18 neutralizing drug, tadekinig alfa, triggering a payment of $30 million and opening the way to a further $650 million in development and commercialization milestones for the Swiss biotech. The rights relate to the use of tadekinig in the treatment of primary pediatric IL-18-driven hyperinflammation, an ultra-rare inherited disorder that if left untreated can lead to multi-organ failure and death.
Bad news from the Novo Nordisk A/S phase III trial called Zeus with IL-6 inhibitor ziltivekimab struck a blow to some drug developers’ theory about heart disease – and to their stocks. An update on the Zeus trial weighing the safety and efficacy of monoclonal antibody ziltivekimab nicked shares of Bagsvaerd, Denmark-based Novo (NYSE:NVO), which closed July 31 at $47.08, down $4.54.
Hainan Shibeikang Biological Medical Technology Co. Ltd. has identified new amino halogenated benzyl derivatives acting as voltage-gated sodium channel blockers potentially useful for the treatment of inflammatory disorders.
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological imprint. At the 26th International AIDS Conference (AIDS 2026), researchers reported persistent abnormalities affecting the gut, cardiovascular system, metabolism and immune function despite effective viral control.
Kolon Tissuegene Inc.’s TG-C, an allogeneic cell and gene therapy candidate for knee osteoarthritis (OA), missed both co-primary endpoints and all key secondary endpoints in a highly anticipated top-line phase III clinical trial readout.
Kolon Tissuegene Inc.’s TG-C, an allogeneic cell and gene therapy candidate for knee osteoarthritis (OA), missed both co-primary endpoints and all key secondary endpoints in a highly anticipated top-line phase III clinical trial readout.
Tianjin Tianyao Pharmaceuticals Co. Ltd. has disclosed receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of systemic inflammatory response syndrome (SIRS), autoimmune disease, lung and kidney injury and sepsis.
Shanghai Pharmaceuticals Holding Co. Ltd. has discovered cyclic peptides acting as interleukin-23 receptor (IL-23R) antagonists found to be potentially useful for the treatment of psoriasis, arthritis and inflammatory bowel disease.
Sightera Biosciences BV announced it has raised €3 million (US$3.5 million) in pre-seed funding. The funding will be used to extend the company’s platform technology and asset portfolio, including its lead program in oncology, SIGHT-001.
Two med-tech companies agreed to settlements with the U.S. government to resolve False Claims Act (FCA) allegations that they submitted Medicare claims for medically unnecessary testing and devices.
RSS
